AZ-话题@MedSci

#AZ#

260篇内容 | 4158人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1714922, encodeId=aecf1e1492233, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=疫苗混打更有效？丹麦研究：混打AZ和mRNA疫苗防护力提升至88%, objectType=article, longId=215398, objectId=69a021539877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a021539877, replyNumber=0, likeNumber=86, createdTime=2022-02-06, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a021539877, moduleTitle=疫苗混打更有效？丹麦研究：混打AZ和mRNA疫苗防护力提升至88%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a021539877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714935, encodeId=24e41e14935bb, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, objectType=article, longId=295681, objectId=0b9e295681bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9e295681bd, replyNumber=0, likeNumber=76, createdTime=2022-10-13, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9e295681bd, moduleTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b9e295681bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714919, encodeId=c6061e14919e4, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率, objectType=article, longId=214570, objectId=899e2145e0f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=899e2145e0f2, replyNumber=0, likeNumber=74, createdTime=2021-11-04, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=899e2145e0f2, moduleTitle=J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=899e2145e0f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714912, encodeId=e1401e149121a, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Ann Hematol：ixazomib口服治疗方案有望成为NDMM患者的良好替代治疗选择, objectType=article, longId=212449, objectId=882221244968, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=882221244968, replyNumber=0, likeNumber=69, createdTime=2022-01-08, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=882221244968, moduleTitle=Ann Hematol：ixazomib口服治疗方案有望成为NDMM患者的良好替代治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=882221244968)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714906, encodeId=9a3b1e14906a2, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz J Otorhinolaryngol：鼻光疗-过敏性鼻炎的替代疗法, objectType=article, longId=208111, objectId=53ed20811142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53ed20811142, replyNumber=0, likeNumber=75, createdTime=2021-05-16, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53ed20811142, moduleTitle=Braz J Otorhinolaryngol：鼻光疗-过敏性鼻炎的替代疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53ed20811142)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714929, encodeId=88ef1e149295b, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性, objectType=article, longId=221370, objectId=59592213e0c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59592213e0c8, replyNumber=0, likeNumber=77, createdTime=2022-05-01, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59592213e0c8, moduleTitle=Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59592213e0c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714927, encodeId=f4021e14927f2, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=AHA 2021丨AMAZE研究：与单独肺静脉隔离相比，使用 LARIAT 辅助左心耳结扎术的结局, objectType=article, longId=220533, objectId=3a9a220533ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a9a220533ab, replyNumber=0, likeNumber=94, createdTime=2022-02-04, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a9a220533ab, moduleTitle=AHA 2021丨AMAZE研究：与单独肺静脉隔离相比，使用 LARIAT 辅助左心耳结扎术的结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a9a220533ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714904, encodeId=cec51e1490417, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=欧盟授权阿斯利康的COVID-19疫苗AZD1222, objectType=article, longId=206439, objectId=16d42064392a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d42064392a, replyNumber=0, likeNumber=96, createdTime=2021-08-06, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d42064392a, moduleTitle=欧盟授权阿斯利康的COVID-19疫苗AZD1222, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d42064392a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714928, encodeId=c2c01e1492841, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Int J Cancer：Pazopanib +FLO (5-FU，奥沙利铂)一线治疗晚期胃癌患者的疗效和安全性：PaFLO研究, objectType=article, longId=221208, objectId=1c1e22120872, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c1e22120872, replyNumber=0, likeNumber=73, createdTime=2022-09-28, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c1e22120872, moduleTitle=Int J Cancer：Pazopanib +FLO (5-FU，奥沙利铂)一线治疗晚期胃癌患者的疗效和安全性：PaFLO研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c1e22120872)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714924, encodeId=e4fd1e149243e, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, objectType=article, longId=215592, objectId=aefb21559219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aefb21559219, replyNumber=0, likeNumber=74, createdTime=2022-01-30, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aefb21559219, moduleTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aefb21559219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714913, encodeId=bb461e14913a2, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, objectType=article, longId=212671, objectId=87bb2126e1d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87bb2126e1d5, replyNumber=0, likeNumber=96, createdTime=2022-02-19, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87bb2126e1d5, moduleTitle=JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87bb2126e1d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714909, encodeId=d9501e14909af, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=逝者：著名癌症研究者，AZ肿瘤研发负责人JoséBaselga去世，享年61岁, objectType=article, longId=208853, objectId=a56420885340, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a56420885340, replyNumber=0, likeNumber=69, createdTime=2022-02-01, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a56420885340, moduleTitle=逝者：著名癌症研究者，AZ肿瘤研发负责人JoséBaselga去世，享年61岁, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a56420885340)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714910, encodeId=00b31e14910c4, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=J Gastroenterology：沃诺拉赞(vonoprazan)在上消化道内镜治疗中预防延迟出血的作用, objectType=article, longId=210309, objectId=f8da2103093c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8da2103093c, replyNumber=0, likeNumber=98, createdTime=2021-10-11, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8da2103093c, moduleTitle=J Gastroenterology：沃诺拉赞(vonoprazan)在上消化道内镜治疗中预防延迟出血的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8da2103093c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714916, encodeId=d60a1e1491680, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Brazilian Journal of Anesthesiology：肥胖患者术中机械通气的个体化与固定化呼气末正压的比较：一项二次分析, objectType=article, longId=213023, objectId=b4f52130232a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4f52130232a, replyNumber=0, likeNumber=86, createdTime=2021-10-21, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4f52130232a, moduleTitle=Brazilian Journal of Anesthesiology：肥胖患者术中机械通气的个体化与固定化呼气末正压的比较：一项二次分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4f52130232a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714918, encodeId=969c1e149189d, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=柳叶刀揭示西班牙疫苗混打AZ疫苗与辉瑞疫苗后特异性抗体显著增高, objectType=article, longId=213406, objectId=1ca2213406cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ca2213406cb, replyNumber=0, likeNumber=85, createdTime=2022-03-12, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ca2213406cb, moduleTitle=柳叶刀揭示西班牙疫苗混打AZ疫苗与辉瑞疫苗后特异性抗体显著增高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ca2213406cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714911, encodeId=25581e1491120, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz J Otorhinolaryngol：巴西儿童早期听力损失的成因, objectType=article, longId=210909, objectId=7cbb2109095e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cbb2109095e, replyNumber=0, likeNumber=76, createdTime=2021-07-20, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cbb2109095e, moduleTitle=Braz J Otorhinolaryngol：巴西儿童早期听力损失的成因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cbb2109095e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714925, encodeId=90161e1492553, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Clin Cancer Res：Ceralasertib(AZD6738)联合紫杉醇或可有效治疗PD1/L1耐药性黑色素瘤, objectType=article, longId=216637, objectId=99fe21663e10, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99fe21663e10, replyNumber=0, likeNumber=131, createdTime=2022-08-15, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99fe21663e10, moduleTitle=Clin Cancer Res：Ceralasertib(AZD6738)联合紫杉醇或可有效治疗PD1/L1耐药性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99fe21663e10)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714923, encodeId=f6a11e1492369, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=美国批准庞贝病药物Nexviazyme, objectType=article, longId=215517, objectId=87a921551e22, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87a921551e22, replyNumber=0, likeNumber=95, createdTime=2022-03-04, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87a921551e22, moduleTitle=美国批准庞贝病药物Nexviazyme, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87a921551e22)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714917, encodeId=e92a1e1491743, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Braz J Otorhinolaryngol：后鼻神经切除术在过敏性鼻炎患者中的长期结果 , objectType=article, longId=213085, objectId=4d1f213085aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d1f213085aa, replyNumber=0, likeNumber=117, createdTime=2022-01-27, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d1f213085aa, moduleTitle=Braz J Otorhinolaryngol：后鼻神经切除术在过敏性鼻炎患者中的长期结果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d1f213085aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1714914, encodeId=68351e149140e, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, objectTitle=Lancet：英国苏格兰数据显示AZ新冠疫苗似乎不如辉瑞新冠疫苗有效, objectType=article, longId=212749, objectId=e8a8212e49c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8a8212e49c1, replyNumber=0, likeNumber=95, createdTime=2021-07-16, rootId=0, userName=12498e5fm22(暂无昵称), userId=9e5031899089, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8a8212e49c1, moduleTitle=Lancet：英国苏格兰数据显示AZ新冠疫苗似乎不如辉瑞新冠疫苗有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8a8212e49c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

AZ

2020-05-29

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

疫苗混打更有效？丹麦研究：混打AZ和mRNA疫苗防护力提升至88%

2022-02-06

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效

2022-10-13

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

J Clin Oncol：5-aza+HSCT可显著提高MDS老年患者的生存率

2021-11-04

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Ann Hematol：ixazomib口服治疗方案有望成为NDMM患者的良好替代治疗选择

2022-01-08

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz J Otorhinolaryngol：鼻光疗-过敏性鼻炎的替代疗法

2021-05-16

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Eur Urol：转移去势抵抗性前列腺癌中，一线化疗药物cabazitaxel和docetaxel的患者偏好性

2022-05-01

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

AHA 2021丨AMAZE研究：与单独肺静脉隔离相比，使用 LARIAT 辅助左心耳结扎术的结局

2022-02-04

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

欧盟授权阿斯利康的COVID-19疫苗AZD1222

2021-08-06

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Int J Cancer：Pazopanib +FLO (5-FU，奥沙利铂)一线治疗晚期胃癌患者的疗效和安全性：PaFLO研究

2022-09-28

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性

2022-01-30

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

JCO: Ixazomi联合来那度胺+地塞米松治疗复发或难治性多发性骨髓瘤（RRMM）的最终分析结果：III期临床研究TOURMALINE-MM1

2022-02-19

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

逝者：著名癌症研究者，AZ肿瘤研发负责人JoséBaselga去世，享年61岁

2022-02-01

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

J Gastroenterology：沃诺拉赞(vonoprazan)在上消化道内镜治疗中预防延迟出血的作用

2021-10-11

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Brazilian Journal of Anesthesiology：肥胖患者术中机械通气的个体化与固定化呼气末正压的比较：一项二次分析

2021-10-21

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

柳叶刀揭示西班牙疫苗混打AZ疫苗与辉瑞疫苗后特异性抗体显著增高

2022-03-12

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz J Otorhinolaryngol：巴西儿童早期听力损失的成因

2021-07-20

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Clin Cancer Res：Ceralasertib(AZD6738)联合紫杉醇或可有效治疗PD1/L1耐药性黑色素瘤

2022-08-15

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

美国批准庞贝病药物Nexviazyme

2022-03-04

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Braz J Otorhinolaryngol：后鼻神经切除术在过敏性鼻炎患者中的长期结果

2022-01-27

12498e5fm22(暂无昵称) (审核中...)

前往app查看评论内容

#AZ#

Lancet：英国苏格兰数据显示AZ新冠疫苗似乎不如辉瑞新冠疫苗有效

2021-07-16

科室
- - 订阅+
  - 更多科室
工具
服务